Russell Investments Group, Ltd. Eagle Pharmaceuticals, Inc. Transaction History

Russell Investments Group, Ltd.

  • $69.8 Billion
  • Q4 2024

A detailed history of Russell Investments Group, Ltd. transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 3,411 shares of EGRX stock, worth $3,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,411
Previous 3,561 4.21%
Holding current value
$3,990
Previous $13,000 92.31%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$0.35 - $3.56 $52 - $534
-150 Reduced 4.21%
3,411 $1,000
Q3 2024

Nov 13, 2024
SELL
$3.71 - $6.07 $23,139 - $37,858
-6,237 Reduced 63.66%
3,561 $13,000
Q2 2024

Aug 08, 2024
BUY
$3.34 - $5.6 $25,003 - $41,921
7,486 Added 323.79%
9,798 $54,000
Q1 2024

May 08, 2024
SELL
$4.26 - $6.51 $50,387 - $77,000
-11,828 Reduced 83.65%
2,312 $12,000
Q4 2023

Feb 05, 2024
SELL
$4.63 - $15.21 $6,134 - $20,153
-1,325 Reduced 8.57%
14,140 $73,000
Q3 2023

Nov 13, 2023
BUY
$15.21 - $22.88 $225,883 - $339,790
14,851 Added 2418.73%
15,465 $243,000
Q2 2023

Aug 10, 2023
SELL
$17.74 - $31.87 $51,073 - $91,753
-2,879 Reduced 82.42%
614 $11,000
Q1 2023

May 09, 2023
SELL
$25.06 - $34.09 $170,408 - $231,812
-6,800 Reduced 66.06%
3,493 $99,000
Q4 2022

Feb 08, 2023
BUY
$24.98 - $39.77 $169,864 - $270,436
6,800 Added 194.68%
10,293 $300,000
Q3 2022

Nov 04, 2022
SELL
$26.42 - $47.12 $77,489 - $138,202
-2,933 Reduced 45.64%
3,493 $92,000
Q2 2022

Jul 29, 2022
SELL
$41.26 - $51.35 $189,259 - $235,542
-4,587 Reduced 41.65%
6,426 $283,000
Q1 2022

May 05, 2022
SELL
$44.58 - $52.6 $92,860 - $109,565
-2,083 Reduced 15.91%
11,013 $543,000
Q4 2021

Jan 21, 2022
SELL
$45.82 - $56.9 $273,637 - $339,806
-5,972 Reduced 31.32%
13,096 $664,000
Q3 2021

Nov 08, 2021
SELL
$43.79 - $55.78 $1.04 Million - $1.33 Million
-23,845 Reduced 55.57%
19,068 $1.06 Million
Q2 2021

Aug 04, 2021
SELL
$36.86 - $44.5 $2.01 Million - $2.43 Million
-54,620 Reduced 56.0%
42,913 $1.82 Million
Q1 2021

May 10, 2021
BUY
$40.32 - $50.97 $496,782 - $628,001
12,321 Added 14.46%
97,533 $4.06 Million
Q4 2020

Feb 08, 2021
SELL
$41.72 - $51.34 $278,522 - $342,745
-6,676 Reduced 7.27%
85,212 $3.96 Million
Q3 2020

Nov 09, 2020
BUY
$37.02 - $51.28 $87,108 - $120,661
2,353 Added 2.63%
91,888 $3.89 Million
Q2 2020

Aug 05, 2020
BUY
$43.24 - $55.02 $1.04 Million - $1.32 Million
24,040 Added 36.71%
89,535 $4.29 Million
Q1 2020

May 06, 2020
BUY
$34.37 - $60.07 $302,559 - $528,796
8,803 Added 15.53%
65,495 $3.01 Million
Q4 2019

Jan 29, 2020
SELL
$54.32 - $64.31 $758,959 - $898,539
-13,972 Reduced 19.77%
56,692 $3.41 Million
Q3 2019

Nov 01, 2019
BUY
$53.25 - $59.98 $1.64 Million - $1.85 Million
30,819 Added 77.35%
70,664 $4 Million
Q2 2019

Aug 09, 2019
BUY
$46.61 - $58.45 $801,225 - $1 Million
17,190 Added 75.88%
39,845 $2.22 Million
Q1 2019

May 13, 2019
BUY
$38.66 - $51.82 $322,733 - $432,593
8,348 Added 58.35%
22,655 $1.14 Million
Q4 2018

Feb 11, 2019
BUY
$36.72 - $67.73 $458,375 - $845,473
12,483 Added 684.38%
14,307 $576,000
Q3 2018

Oct 26, 2018
SELL
$66.65 - $83.86 $267,133 - $336,110
-4,008 Reduced 68.72%
1,824 $126,000
Q2 2018

Aug 08, 2018
BUY
$51.25 - $76.62 $2,716 - $4,060
53 Added 0.92%
5,832 $441,000
Q1 2018

May 11, 2018
BUY
$52.16 - $66.86 $256,001 - $328,148
4,908 Added 563.49%
5,779 $304,000
Q4 2017

Feb 06, 2018
SELL
$49.6 - $60.87 $2,033 - $2,495
-41 Reduced 4.5%
871 $48,000
Q3 2017

Nov 07, 2017
BUY
$46.62 - $60.36 $42,517 - $55,048
912
912 $54,000

Others Institutions Holding EGRX

# of Institutions
15
Shares Held
498K
Call Options Held
0
Put Options Held
0
View Full List

About EAGLE PHARMACEUTICALS, INC.

EGRX Quotes by TradingView
  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $15.2M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email